| Autor: |
Pisetsky DS; Department of Medicine and Immunology, Medical Research Service, Durham VA Hospital, NC 27705, USA. piset001@mc.duke.edu, Grammer AC, Ning TC, Lipsky PE |
| Jazyk: |
angličtina |
| Zdroj: |
Nature reviews. Rheumatology [Nat Rev Rheumatol] 2011 Aug 02; Vol. 7 (9), pp. 551-6. Date of Electronic Publication: 2011 Aug 02. |
| DOI: |
10.1038/nrrheum.2011.108 |
| Abstrakt: |
B-cell-directed therapy-the use of agents that eliminate B cells or block cytokines important for B-cell function-is emerging as a promising approach to the treatment of rheumatic disease. Target diseases, including systemic lupus erythematosus (SLE), display diverse patterns of autoantibody production and aberrant activation of B cells. Despite the success of this general approach, the mechanisms by which B-cell-directed therapy ameliorates disease, and the role of autoantibodies as biomarkers of clinical response remain unclear. Importantly, although B-cell-directed therapy can reduce the production of some autoantibodies, the effects can be variable and heterogeneous, probably reflecting the critical (but ill-defined) roles of different B-cell and plasma cell populations in autoantibody production. Future studies during clinical trials of these agents are needed to define which B-cell and autoantibody populations are affected (or ought to be), and to discover informative biomarkers of clinical response that can be used to advance this therapeutic approach. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
